Home LiteratureArticle Details
PMID: 27878117 Published · epublish English Review Journal Article

GPC-3 in hepatocellular carcinoma: current perspectives.

Journal of hepatocellular carcinoma ·Vol. 3 ·2016-00-00 ·Pages 63-67

Wu Y, Liu H, Ding H

Abstract

Glypican-3 (GPC3), a member of heparan sulfate proteoglycans, attaches to the cell membrane and is frequently observed to be elevated in hepatocellular carcinoma (HCC). However, GPC3 is not detected in normal liver tissues and benign liver lesions. Consequently, GPC3 is currently being used as a diagnostic biomarker and HCC-specific positron emission computed tomography probe to identify HCCs in normal liver tissues and benign liver lesions. The overexpression of GPC-3 in serum or liver tissue also predicts poor prognosis for HCC patients. In addition, GPC3 promotes HCC growth and metastasis by activating the canonical Wnt and other signaling pathways. Targeting of GPC3, including GC33, HN3 and YP7, might offer new immunotherapeutic tools for HCC treatment.

Keywords
diagnostics glypican-3 hepatocellular carcinoma immunotherapy prognosis
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Wu Yongle
Department of Gastroenterology and Hepatology.
Liu Hui
Department of Pathology, Beijing You'an Hospital, Affiliated with Capital Medical University, Beijing, People's Republic of China.
Ding Huiguo
Department of Gastroenterology and Hepatology.
Conflict of Interest

The authors report no conflicts of interest in this work.

References (39)
39 references, click to expand
  1. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
    Surgery. 2013 Sep;154(3):536-44 PMID: 23601901
  2. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution.
    Cancer Res. 1997 Nov 15;57(22):5179-84 PMID: 9371521
  3. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis.
    Hepatology. 2011 Mar;53(3):854-64 PMID: 21319186
  4. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.
    Nat Commun. 2015 Mar 11;6:6536 PMID: 25758784
  5. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding.
    Dev Cell. 2008 May;14 (5):700-11 PMID: 18477453
  6. Diagnosis accuracy of serum Glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis.
    Eur Rev Med Pharmacol Sci. 2015 Oct;19(19):3655-73 PMID: 26502856
  7. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.
    Cancer Res. 2005 Jul 15;65(14):6245-54 PMID: 16024626
  8. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
    Acta Histochem. 2012 Oct;114(6):547-52 PMID: 22119409
  9. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region.
    Gut Liver. 2016 May 23;10 (3):332-9 PMID: 27114433
  10. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
    Int J Mol Med. 2011 Oct;28(4):497-503 PMID: 21617840
  11. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
    Int J Oncol. 2015 Mar;46(3):1275-85 PMID: 25572615
  12. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
    Mod Pathol. 2005 Dec;18(12):1591-8 PMID: 15920546
  13. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
    Cancer Res. 2008 Dec 1;68(23):9832-8 PMID: 19047163
  14. Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis.
    World J Gastroenterol. 2014 May 28;20(20):6336-44 PMID: 24876756
  15. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma.
    Liver Int. 2011 Jan;31(1):120-31 PMID: 20964802
  16. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
    FEBS J. 2013 May;280(10):2471-6 PMID: 23305321
  17. Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients.
    Afr Health Sci. 2013 Sep;13(3):703-9 PMID: 24250310
  18. Glypicans.
    Genome Biol. 2008;9(5):224 PMID: 18505598
  19. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples.
    Am J Clin Pathol. 2008 Jun;129(6):899-906 PMID: 18480006
  20. Glypican-3 antibodies: a new therapeutic target for liver cancer.
    FEBS Lett. 2014 Jan 21;588(2):377-82 PMID: 24140348
  21. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
    Bioconjug Chem. 2016 Mar 16;27(3):831-9 PMID: 26850086
  22. Glypican-3: a new target for cancer immunotherapy.
    Eur J Cancer. 2011 Feb;47(3):333-8 PMID: 21112773
  23. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma.
    Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1718-24 PMID: 21940340
  24. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
    Anticancer Drugs. 2010 Nov;21(10):907-16 PMID: 20847643
  25. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Clin Cancer Res. 2014 Dec 15;20(24):6418-28 PMID: 25320357
  26. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
    Biochem Biophys Res Commun. 2009 Jan 9;378(2):279-84 PMID: 19022220
  27. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
    Cancer Sci. 2009 Aug;100(8):1403-7 PMID: 19496787
  28. Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface.
    Biochem J. 2008 Mar 15;410(3):503-11 PMID: 17967162
  29. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
    Gastroenterology. 2006 Dec;131(6):1758-67 PMID: 17087938
  30. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.
    Hepatology. 2012 Oct;56(4):1380-90 PMID: 22706665
  31. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
    Gastroenterology. 2003 Jul;125(1):89-97 PMID: 12851874
  32. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.
    Gut. 2001 Apr;48(4):558-64 PMID: 11247902
  33. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.
    J Nucl Med. 2014 May;55(5):799-804 PMID: 24627434
  34. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis.
    BMC Cancer. 2014 Feb 18;14:104 PMID: 24548704
  35. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
    Clin Cancer Res. 2013 Feb 15;19(4):920-8 PMID: 23362325
  36. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2.
    Neoplasia. 2011 Aug;13(8):735-47 PMID: 21847365
  37. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease.
    J Clin Invest. 2009 Jun;119(6):1438-49 PMID: 19487820
  38. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.
    World J Gastroenterol. 2010 Sep 21;16(35):4410-5 PMID: 20845507
  39. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.
    Int J Cancer. 2010 Mar 15;126(6):1291-301 PMID: 19816934
Article Info
Journal
Journal of hepatocellular carcinoma
Abbr.
J Hepatocell Carcinoma
ISSN
2253-5969
DOI
10.2147/JHC.S116513
Published
2016-00-00
Epub
2016-00-08
Pages
63-67
Language
English
Region
New Zealand
NLM ID
101674775
PMCID
PMC5108608
External Links
PubMed source DOI: 10.2147/JHC.S116513 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2